Diagnostic role of CXCL13 biomarker in primary Sjogren's syndrome patients with parotid non-Hodgkin's lymphoma complication.
Med Clin (Barc)
; 160(11): 484-488, 2023 06 09.
Article
en En, Es
| MEDLINE
| ID: mdl-37005121
ABSTRACT
INTRODUCTION:
Serum biomarkers are important predictive factors for development of parotid non-Hodgkin's lymphoma (NHL) complication in primary Sjogren's syndrome (pSS) patients. The aim was to evaluate the diagnostic accuracy of serum CXCL13 chemokine in pSS patients with parotid NHL complication. MATERIAL ANDMETHODS:
Serum CXCL13 chemokine was assessed in 33 patients with pSS [7 with parotid NHL complication (pSS+NHL subgroup) and 26 without NHL (pSS-NHL subgroup)] and 30 healthy subjects.RESULTS:
The serum CXCL13 levels in pSS+NHL subgroup [175.2 (107.9-220.4) pg/ml] were significantly higher comparing to the healthy subjects group (p=0.018) and the pSS-NHL subgroup (p=0.048). A cut-off value of 123.45pg/ml (Se=71.4%, Sp=80.8%, AUROC=0.747) was established for parotid lymphoma diagnosis.CONCLUSION:
The serum CXCL13 biomarker could be considered a valuable tool for the diagnosis of parotid NHL complication in pSS patients.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Linfoma no Hodgkin
/
Neoplasias de la Parótida
/
Síndrome de Sjögren
/
Linfoma
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
/
Es
Revista:
Med Clin (Barc)
Año:
2023
Tipo del documento:
Article
País de afiliación:
Rumanía